D
Dorcas Fulton
Researcher at University of Alberta
Publications - 53
Citations - 4783
Dorcas Fulton is an academic researcher from University of Alberta. The author has contributed to research in topics: Radiation therapy & Glioma. The author has an hindex of 31, co-authored 53 publications receiving 4478 citations. Previous affiliations of Dorcas Fulton include University of California, San Francisco & Cross Cancer Institute.
Papers
More filters
Journal ArticleDOI
Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial
Wilson Roa,P. M.A. Brasher,Glenn Bauman,M. Anthes,Eduardo Bruera,A. Chan,B. Fisher,Dorcas Fulton,Sunil Gulavita,Chunhai Hao,S. Husain,Amy P. Murtha,Kenneth C. Petruk,Dawn D. Stewart,P. Tai,Raul C. Urtasun,J. G. Cairncross,P. Forsyth +17 more
TL;DR: In view of the similar KPS scores, decreased increment in corticosteroid requirement, and reduced treatment time, the abbreviated course of RT seems to be a reasonable treatment option for older patients with glioblastoma multiforme.
Journal ArticleDOI
Metabolic Modulation of Glioblastoma with Dichloroacetate
Evangelos D. Michelakis,Gopinath Sutendra,Peter Dromparis,Linda Webster,Alois Haromy,E. Niven,C. Maguire,John R. Mackey,Dorcas Fulton,Bassam Abdulkarim,Michael Sean McMurtry,K. C. Petruk +11 more
TL;DR: Dichloroacetate appears to be safe to give to humans at doses that are required for pyruvate dehydrogenase inhibition, and can be added to a growing group of metabolic modulators that may prove useful in cancer therapy.
Journal ArticleDOI
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
Gregory Cairncross,David R. Macdonald,S Ludwin,D Lee,T L Cascino,Jan C. Buckner,Dorcas Fulton,E Dropcho,Douglas A. Stewart,C Schold +9 more
TL;DR: The rate and duration of response of anaplastic oligodendrogliomas to a dose-escalated combination chemotherapy regimen consisting of procarbazine, lomustine, and vincristine and the side effects of this treatment were examined.
Journal ArticleDOI
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James Perry,Karl Belanger,Warren P. Mason,Dorcas Fulton,Petr Kavan,Jacob C. Easaw,Claude Shields,Sarah Kirby,David R. Macdonald,David D. Eisenstat,Brian Thiessen,Peter A. Forsyth,Jean-François Pouliot +12 more
TL;DR: Rechallenge with continuous dose-intense TMZ 50 mg/m(2)/d is a valuable therapeutic option for patients with recurrent GBM and patients who experience progression during the first six cycles of conventional adjuvant TMZ therapy or after a treatment-free interval get the most benefit from therapy.
Journal ArticleDOI
Which glioblastoma multiforme patient will become a long-term survivor? A population-based study.
James N. Scott,N B Rewcastle,P. M. A. Brasher,Dorcas Fulton,J. A. MacKinnon,Mark G. Hamilton,Mark G. Hamilton,J. G. Cairncross,P. Forsyth +8 more
TL;DR: Conventionally treated GBM patients in an unselected population have a very small chance of long-term survival, but the use of aggressive surgical resection and adjuvant chemotherapy may make long‐term survival more likely in G BM patients if their performance status is high at diagnosis.